Diagnostic performance of microRNAs in testicular germ cell tumors: a systematic review and meta-analysis

The sensitivity (Sen) of classic biomarkers for the diagnosis of testicular germ cell tumors (TGCTs) is currently low. Previous studies have shown the diagnostic potential of microRNAs (miRNAs) for TGCTs; however, the results of these studies are inconsistent. Therefore, we conducted a systematic review and meta-analysis to evaluate their diagnostic value. PubMed, EMBASE, Cochrane Library, and Web of Science databases were systematically searched until September 30, 2020 and 18 trials from 11 studies involving 2,068 participants were included in this meta-analysis. Using a bivariate mixed-effects meta-analysis model, the pooled Sen, specificity (Spe), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) with 95% confidence interval values of total miRNAs were 0.83 (0.73–0.90), 0.95 (0.89–0.98), 15.79 (7.41–33.66), 0.18 (0.11–0.29), 87.13 (41.99–180.82), and 0.95 (0.93–0.97), respectively; however, the observed values of single miR-371a-3p were 0.84 (0.76–0.90), 0.95 (0.91–0.98), 18.41 (9.69–34.97), 0.17 (0.11–0.26), 111.56 (47.72–260.80), and 0.97 (0.95–0.98), respectively. Subgroup analysis revealed that miRNAs that included miR-371a-3p showed higher predictive performance than those that did not (P < 0.05). This research identified that miR-371a-3p has a high diagnostic value for TGCTs, except teratoma.